Liver Cancer
Copyright ©The Author(s) 2004.
World J Gastroenterol. Aug 1, 2004; 10(15): 2195-2200
Published online Aug 1, 2004. doi: 10.3748/wjg.v10.i15.2195
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Proliferation of ECV304 inhibited by the supernant of BHK-21 transfected with pSecES and proliferation of spleen lymphocytes stimulated by the supernant of BHK-21 trans-fected with pmIL-12. Each bar represents A value of ECV304 or spleen lymphocytes, and mean ± SD for 5 wells. aP < 0.05 vs control, bP < 0.01 vs control.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Hepatoma formation and growth inhibited by gene therapy of endostatin and IL- 12. Each bar represents tumor weight of mice treated with PVP/NaCl, pcDNA3.1/PVP, pSecES/PVP, pmIL-12/PVP or pSecES + pmIL-12/PVP, and mean ± SD for six mice. P < 0.01 by ANOVA analysis.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Increase of mice serum endostatin levels or IL-12 levels after gene therapy. A: Serum endostatin levels of mice treated with pcDNA3.1/PVP, pSecES/PVP, pSecES + pmIL-12/PVP or not inoculated with H22 cells (basic levels). Each bar represents mean ± SD for six mice. aP < 0.05 vs pcDNA3.1 group. B: Serum IL-12 levels of mice treated with pcDNA3.1/PVP, pmIL-12/PVP, pSecES + pmIL-12/PVP. Each bar represents mean ± SD for six mice. aP < 0.05 vs pcDNA3.1 group.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Hepatoma angiogenesis inhibited by gene therapy of endostatin and IL-12. MVD (CD31staining, 200 × ) of hepatoma treated with pSecES/PVP (7.3 ± 1.2) (B), pmIL-12/PVP (10.0 ± 1.7) (C) or pSecES + pmIL-12/PVP (3.7 ± 1.2) (D) was less than that treated with pcDNA3.1/PVP (22.7 ± 3.1, P < 0.05) (A).
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Lymphocytes infiltration into hepatoma promoted by gene therapy of IL-12. TILs (HE staining, 400 × ) of hepatoma treated with pmIL-12/PVP (146.2 ± 24.6) (B) and pSecES + pmIL-12/PVP (123.2 ± 21.4) (C) were more than that treated with pcDNA3.1/PVP (45.2 ± 11.8, P < 0.01) (A).
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Apoptosis of hepatoma cells induced by gene therapy of endostatin and IL-12. Apaptotic tumor cells (TUNEL, 400 × ) treated with pSecES/PVP (11.2 ± 2.3) (B), pmIL-12/PVP (14.4 ± 3.5) (C) or pSecES + pmIL-12/PVP (24.8 ± 4.8) (D) were more than those treated with pcDNA3.1/PVP (1.4 ± 1.7, P < 0.05) (A).